ScreenerHero

ADAGAdagene Inc.

NAS · US · Healthcare · Biotechnology · adagene.com
4.020USDMkt Cap: 265.61M $P/E: —

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap265.61M $
Enterprise Value164.65M $
Revenue (TTM)9.29M $
Gross Profit9.29M $
Net Income (TTM)-17.61M $
Revenue/Share0.1790 USD
Last Price4.020 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees128
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0053291078
Valuation
P/E (Trailing)—
P/E (Forward)-7.18
PEG—
EV/EBITDA-7.50
EV/Revenue17.72
P/S28.59
P/B3.02
EPS (TTM)-0.37
EPS (Forward)-0.56
52W Range
3.97034% of range4.115
52W High4.115 USD
52W Low3.970 USD
Profitability
Gross Margin100.00%
Oper. Margin-1023.92%
EBITDA Margin-236.28%
Profit Margin-229.56%
ROE-49.82%
ROA-22.50%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.66M $
CapEx (TTM)17.05K $
FCF Margin-130.87%
FCF Yield-4.58%
Net Debt-121.82M $
Net Debt/EBITDA5.55
Balance Sheet
Debt/Equity0.18
Current Ratio5.02
Quick Ratio4.86
Book Value/Sh1.332 USD
Cash/Share1.905 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.74 USD
Upside (mean)+167.2%
Target Range7.000 USD – 17.45 USD
$7.000+167.2% to mean$17.45
# Analysts6
Ownership
Shares Out.66.07M
Float42.17M
Insiders21.29%
Institutions36.64%
Short Interest
Short Ratio7.3d
Short % Float4.08%
Short % Out.3.46%
Shares Short2.29M
Short (prev mo.)2.08M
Technical
SMA 503.850 (+4.4%)
SMA 2003.124 (+28.7%)
Beta0.57
S&P 52W Chg19.18%
Avg Vol (30d)61.29K
Avg Vol (10d)334.26K
Technical Indicators
RSI (14)55.1
MACD0.0679
MACD Signal0.0437
MACD Hist.+0.0242
BB Upper4.292 USD
BB Middle3.873 USD
BB Lower3.453 USD
BB Width21.66%
ATR (14)0.3043 USD
Vol Ratio (20d)0.21x